TNF inhibitors have emerged as the drug of choice for the treatment of DADA2 for the vasculitic phenotype though there are no randomised controlled trials available.4 In severe disease with haematological involvement or immunodeficiency, l ong-term s uccess with allogenic hematopoietic stem cell transplantation has been reported.3, 6. This evidence concerns the gene TNF and immunodeficiency disease.